^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Yescarta (axicabtagene ciloleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published date:
12/11/2023
Excerpt:
Gilead Company (Nasdaq: GILD), today announced results from a three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) as first-line treatment after two cycles of chemoimmunotherapy in patients with high-risk, large b-cell lymphoma (LBCL). The analysis, which demonstrated durability of clinical benefit – both high complete response (CR) and objective response rates (ORR), including in patients with MYC and BCL2 and/or BCL6 rearrangements (also known as double- or triple-hit histology).
